CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
Intravenous (IV) and oral Vitamin Cdrug
Likely dose
Intravenous (IV) and oral Vitamin C 50 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03613727
NCT03613727Phase 2Completed
CompareCT.gov

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

Virginia Commonwealth University·interventional·Posted Aug 3, 2018·Updated Nov 7, 2023

In Brief

A Phase 2 clinical trial evaluating Intravenous (IV) and oral Vitamin C for Lymphoid Leukemia and 3 related conditions. Completed, enrolled 61 participants across 1 site.

Detailed Summary

This phase 2 trial studies the effect of intravenous (IV) vitamin C repletion after myeloablative allogeneic stem cell transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoid Leukemia, Myeloid Leukemia, Monocytic Leukemia, Myelodysplasia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 3, 2018
Enrollment StartOct 1, 2018
Primary CompletionOct 6, 2022
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 7.9 years ago

Interventions

Intravenous (IV) and oral Vitamin Cdrug

Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours • After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180